Mesoblast's remestemcel-L shows 75% survival rate in children with severe form of graft-versus-host disease [Seeking Alpha]
Mesoblast Limited - American Depositary Shares (MESO)
US:NASDAQ Investor Relations:
investorsmedia.mesoblast.com
Company Research
Source: Seeking Alpha
Mesoblast's remestemcel-L shows 75% survival rate in children with severe form of graft-versus-host diseaseAdditional data from a Phase 3 clinical trial evaluating Mesoblast Limited's (NASDAQ:MESO) allogeneic mesenchymal stem cell product candidate, remestemcel-L, in children with steroid-refractory acute graft-versus-host disease (aGvHD) showed a significant impact on survival. The results were presented at the International Society for Stem Cell Research Annual Meeting in Melbourne, Australia.As reported in February, the study met the primary endpoint of overall response rate. Day 100 results showed an 87% survival rate for day 28 responders (n=33/38) and an overall survival rate of 75% (n=41/55).The company says typical day 100 mortality can reach 70% in patients who fail to respond to initial steroid therapy while 12-mortality is almost 90%.Mesoblast believes the data may be sufficient to support a U.S. marketing application under accelerated review status since there are no appro
Show less
Read more
Impact Snapshot
Event Time:
MESO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MESO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MESO alerts
High impacting Mesoblast Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MESO
News
- Degenerative Disc Disease Market Forecast - 2032; NSAIDs, Opioids, and others are major revenue generators [Yahoo! Finance]Yahoo! Finance
- Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc. [Yahoo! Finance]Yahoo! Finance
- Mesoblast Limited: Back From The Dead [Seeking Alpha]Seeking Alpha
- Mesoblast Limited (NASDAQ: MESO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) Acquire Media Monitor